Mattioli Maria Alessandra, Benzecry Valentina, Murgia Giulia, Denaro Nerina, Marzano Angelo Valerio, Passoni Emanuela, Nazzaro Gianluca
Department of Physiopathology and Transplantation, University of Milan.
Dermatology Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore, Milan.
Dermatol Reports. 2025 May 23;17(2). doi: 10.4081/dr.2024.10152. Epub 2024 Nov 20.
Basal cell carcinoma (BCC) is the most common non-melanoma skin cancer. BCCs are categorized into "easy-to-treat" and "difficult-to-treat" groups, with the latter including all BCCs that are challenging to manage due to technical, patient-related, or tumor-related factors, such as locally advanced BCCs. In this report, we describe an 84-year-old patient with an extensive, unilateral BCC. Following a decision by the multidisciplinary skin cancer board, the patient was successfully treated with a daily dose of 200 mg of sonidegib, an inhibitor of the Hedgehog pathway, for eight months, acquiring complete clinical and histopathological remission. No significant side effects were reported. The follow-up period of 24 months has shown no negative results.
基底细胞癌（BCC）是最常见的非黑色素瘤皮肤癌。BCC分为“易于治疗”和“难以治疗”两组，后者包括所有由于技术、患者相关或肿瘤相关因素（如局部晚期BCC）而难以处理的BCC。在本报告中，我们描述了一名84岁患有广泛单侧BCC的患者。经多学科皮肤癌委员会决定，该患者成功接受了每日剂量200mg的索尼德吉（一种Hedgehog通路抑制剂）治疗，为期8个月，实现了完全的临床和组织病理学缓解。未报告明显的副作用。24个月的随访期未显示出负面结果。
